Celgene

Celgene company information, Employees & Contact Information

Explore related pages

Celgene email format Celgene management contacts

Related company profiles:

We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to continue to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases. For more information on the acquisition, see our press release at: http://bit.ly/3UbQcnl

Company Details

Employees
2.23K
Address
86 Morris Avenue, Summit,new Jersey 07901,united States
Phone
+1-908-673-9000
Email
dr****@****ene.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
celgene.com
Keywords
Hematology, Oncology, Inflammation, Immunology, Cancer, R&D, Innovation, Immunooncology, biopharma, Epigenetics, Protein Homeostasis, Translation Medicine, Orphan diseases.
HQ
Summit, New Jersey
Competitors
Pfizer, AbbVie, Eli Lilly and Company, Amgen, AstraZeneca, Novartis, Bristol Myers Squibb, Celegence, Sanofi, GSK.
Looking for a particular Celgene employee's phone or email?

Celgene Questions

News

Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis - PR Newswire

Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis PR Newswire

Celgene Q3 16 Earnings Conference Call At 9:00 AM ET - RTTNews

Celgene Q3 16 Earnings Conference Call At 9:00 AM ET RTTNews

Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion (Published 2019) - The New York Times

Bristol-Myers to Acquire Celgene in Deal Worth $74 Billion (Published 2019) The New York Times

Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database - Wiley Online Library

Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database Wiley Online Library

Deal of the Year: Bristol-Myers Squibb buys Celgene - BioPharma Dive

Deal of the Year: Bristol-Myers Squibb buys Celgene BioPharma Dive

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis - The New England Journal of Medicine

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis The New England Journal of Medicine

Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases - Fierce Pharma

Celgene Completes Acquisition of Receptos, Advancing Leadership in Immune-Inflammatory Diseases Fierce Pharma

Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing - statnews.com

Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing statnews.com

Celgene pens pact to join Bristol-Myers, Pfizer in R&D race - Fierce Biotech

Celgene pens pact to join Bristol-Myers, Pfizer in R&D race Fierce Biotech

Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies - CNBC

Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies CNBC

Juno stock skyrockets after Celgene invests $1 billion to change the way cancer is treated - GeekWire

Juno stock skyrockets after Celgene invests $1 billion to change the way cancer is treated GeekWire

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent - ScienceDirect.com

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent ScienceDirect.com

Kaposi Sarcoma Treatment Gets Breakthrough Therapy Designation - - Oncology Nurse Advisor

Kaposi Sarcoma Treatment Gets Breakthrough Therapy Designation - Oncology Nurse Advisor

NHGRI collaborates with Smithsonian to produce new genome exhibit - National Human Genome Research Institute (.gov)

NHGRI collaborates with Smithsonian to produce new genome exhibit National Human Genome Research Institute (.gov)

A glimpse inside Bristol Myers Squibb’s integration with Celgene - PharmaVoice

A glimpse inside Bristol Myers Squibb’s integration with Celgene PharmaVoice

Bristol-Myers Squibb to Acquire Celgene for $74B - Genetic Engineering and Biotechnology News

Bristol-Myers Squibb to Acquire Celgene for $74B Genetic Engineering and Biotechnology News

Celgene and IBM Watson Health Forge Collaboration Designed to Transform Patient Safety Monitoring - PR Newswire

Celgene and IBM Watson Health Forge Collaboration Designed to Transform Patient Safety Monitoring PR Newswire

Celgene Corp To Present At Wells Fargo Healthcare Conference;Webcast At 10:05AM - RTTNews

Celgene Corp To Present At Wells Fargo Healthcare Conference;Webcast At 10:05AM RTTNews

BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS - Fierce Pharma

BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS Fierce Pharma

The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss - Fierce Pharma

The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss Fierce Pharma

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal - Reuters

Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal Reuters

Celgene bags Beigene PD-1 drug for $263M up front - Fierce Biotech

Celgene bags Beigene PD-1 drug for $263M up front Fierce Biotech

‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents - statnews.com

‘You just got better at making money’: Democrats blast Celgene, Teva for price hikes detailed in internal documents statnews.com

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma - The New England Journal of Medicine

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma The New England Journal of Medicine

Celgene to fork over $280M to wrap a whistleblower's Revlimid marketing claims - Fierce Pharma

Celgene to fork over $280M to wrap a whistleblower's Revlimid marketing claims Fierce Pharma

A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase - PNAS

A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase PNAS

Celgene, say goodbye to Otezla: BMS agrees to sell psoriasis drug to clear $74B merger - Fierce Pharma

Celgene, say goodbye to Otezla: BMS agrees to sell psoriasis drug to clear $74B merger Fierce Pharma

Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan - Fierce Pharma

Bristol Myers Squibb, after massive Celgene takeover, plots $15B buyback plan Fierce Pharma

Bristol-Myers Squibb is buying Celgene in a $74 billion deal - businessinsider.com

Bristol-Myers Squibb is buying Celgene in a $74 billion deal businessinsider.com

Does Bristol-Myers have a plan B if activists scuttle its Celgene buy? - Fierce Pharma

Does Bristol-Myers have a plan B if activists scuttle its Celgene buy? Fierce Pharma

Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace

Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments BioSpace

J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact Biomedicines - Fierce Biotech

J.P. Morgan kicks off with a deal as Celgene pays $1.1B for Impact Biomedicines Fierce Biotech

Celgene buys Juno for $9B, deepening bet on CAR-T - BioPharma Dive

Celgene buys Juno for $9B, deepening bet on CAR-T BioPharma Dive

Lenalidomide as Maintenance Therapy in Multiple Myeloma After Autologous Stem Cell Transplantation - The ASCO Post

Lenalidomide as Maintenance Therapy in Multiple Myeloma After Autologous Stem Cell Transplantation The ASCO Post

Celgene to buy Juno for $9 billion to boost cancer pipeline - Reuters

Celgene to buy Juno for $9 billion to boost cancer pipeline Reuters

Celgene in Asia-Pacific collab with Antengene, Tigermed as clinical support - Fierce Biotech

Celgene in Asia-Pacific collab with Antengene, Tigermed as clinical support Fierce Biotech

BMS Completes $74 Billion Celgene Takeover - BioSpace

BMS Completes $74 Billion Celgene Takeover BioSpace

At Long Last, Bristol-Myers Buys Celgene - Barron's

At Long Last, Bristol-Myers Buys Celgene Barron's

Celgene's MS drug ozanimod gets EU filing, with FDA submission to follow - Fierce Biotech

Celgene's MS drug ozanimod gets EU filing, with FDA submission to follow Fierce Biotech

Celgene pledges to limit price hikes—or does it? - Fierce Pharma

Celgene pledges to limit price hikes—or does it? Fierce Pharma

BMS completes $74bn Celgene acquisition - PharmaTimes

BMS completes $74bn Celgene acquisition PharmaTimes

FDA Approves ABRAXANE® for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer - CNBC

FDA Approves ABRAXANE® for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer CNBC

Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 - Fierce Biotech

Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 Fierce Biotech

Celgene, Takeda invest in intratumoral microdosing firm Presage - Fierce Biotech

Celgene, Takeda invest in intratumoral microdosing firm Presage Fierce Biotech

Celgene Can’t Cure the Biotech Blues - The Wall Street Journal

Celgene Can’t Cure the Biotech Blues The Wall Street Journal

Celgene cans phase 3 trial of $710M Crohn’s drug GED-0301 - Fierce Biotech

Celgene cans phase 3 trial of $710M Crohn’s drug GED-0301 Fierce Biotech

Tribeca Film’s “200 Miles” Documents Cancer Advocate's Record Run for Multiple Myeloma Research Foundation - MultiVu

Tribeca Film’s “200 Miles” Documents Cancer Advocate's Record Run for Multiple Myeloma Research Foundation MultiVu

Sprouting a career in regenerative medicine - Science | AAAS

Sprouting a career in regenerative medicine Science | AAAS

Companies like Celgene

Celegence logo - Similar company to Celgene

Celegence

174
Eli Lilly and Company logo - Similar company to Celgene

Eli Lilly And Company

51.50K
AbbVie logo - Similar company to Celgene

Abbvie

57.01K
Sanofi logo - Similar company to Celgene

Sanofi

88.33K
Pfizer logo - Similar company to Celgene

Pfizer

100.69K
Amgen logo - Similar company to Celgene

Amgen

35.77K
GSK logo - Similar company to Celgene

Gsk

90.45K
Bristol Myers Squibb logo - Similar company to Celgene

Bristol Myers Squibb

38.47K
AstraZeneca logo - Similar company to Celgene

Astrazeneca

78.61K
Novartis logo - Similar company to Celgene

Novartis

79.78K

Top Celgene Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant